Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

17.79 -0.59 (-3.21%)

Streaming Delayed Price Updated: 9:36 AM EDT, Jul 10, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	21,915
Open	18.16
Bid (Size)	17.67 (300)
Ask (Size)	17.91 (100)
Prev. Close	18.38
Today's Range	17.62 - 18.34
52wk Range	6.900 - 19.15
Shares Outstanding	67,176,067
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026

June 23, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape ↗

June 10, 2026

Amylyx Pharmaceuticals (NASDAQ:AMLX) Co-Chief Executive Officer Justin Klee said the company is preparing for a key Phase 3 readout for avexitide, its lead program for post-bariatric hypoglycemia,...

Via MarketBeat

Performance

YTD	+55.8%	+55.8%
1 Month	+31.3%	+31.3%
3 Month	+2.7%	+2.7%
6 Month	+50.4%	+50.4%
1 Year	+145.7%	+145.7%

More News

Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026

June 08, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

What to Know About This Fund's $10 Million Bet on Gold Miners ↗

May 24, 2026

Via The Motley Fool

Amylyx Pharmaceuticals (NASDAQ:AMLX) Q1 Loss Slightly Wider Than Expected as All Eyes Turn to Q3 Avexitide Trial Data ↗

May 07, 2026

Via Chartmill

Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) Reports Narrower-Than-Expected Q4 Loss, Focus Remains on Key 2026 Data ↗

March 03, 2026

Via Chartmill

Amylyx Stock: Why the Full Pipeline Story Matters ↗

May 24, 2026

Via MarketBeat

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗

May 19, 2026

Via The Motley Fool

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗

May 19, 2026

Via The Motley Fool

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation

May 15, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus ↗

May 14, 2026

Via MarketBeat

Amylyx (AMLX) Q1 2026 Earnings Transcript ↗

May 08, 2026

Via The Motley Fool

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

May 07, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

May 06, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

May 05, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

April 30, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

April 08, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

March 24, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx (AMLX) Q4 2025 Earnings Call Transcript ↗

March 03, 2026

Via The Motley Fool

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

March 03, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

February 26, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗

February 25, 2026

Via The Motley Fool

This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗

February 25, 2026

Via The Motley Fool

Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗

February 25, 2026

Via The Motley Fool

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

February 24, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Frequently Asked Questions

Is Amylyx Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Amylyx Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Amylyx Pharmaceuticals, Inc. - Common Stock trade on?

Amylyx Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock is AMLX on the Nasdaq Stock Market

What is the current price of Amylyx Pharmaceuticals, Inc. - Common Stock?

The current price of Amylyx Pharmaceuticals, Inc. - Common Stock is 17.79

When was Amylyx Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Amylyx Pharmaceuticals, Inc. - Common Stock was at 07/10/26 09:36 AM ET

What is the market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock is 1.20B

How many shares of Amylyx Pharmaceuticals, Inc. - Common Stock are outstanding?

Amylyx Pharmaceuticals, Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.